A Martorell, S Santos-Alarcón, A Sahuquillo-Torralba, R Rivera-Díaz, I Belinchón-Romero, D Ruiz-Genao, A Romero-Maté, R Ruiz-Villaverde, M Ferrán-Farrés, F Gallardo-Hernández, M Almenara-Blasco, J Alonso-Suárez, Á González-Cantero, E Martínez-Lorenzo, J M Fernández-Armenteros, E de Alcázar-Viladomiu, J García-Latasa, V Rocamora-Durant, M Ara-Martín, A Mateu-Puchades, M Llamas-Velasco, E Vilarrasa-Rull, M Velasco-Pastor, P De la Cueva, J M Carrascosa, J Magdaleno-Tapial
BACKGROUND AND OBJECTIVE: risankizumab-a humanized monoclonal antibody that targets the p19 subunit of IL-23-has been recently approved to treat moderate-to-severe plaque psoriasis. Real-world data based on a representative pool of patients are currently lacking. OBJECTIVE: To assess the mid- and long-term safety and efficacy profile of risankizumab in patients with moderate-to-severe psoriasis in the routine clinical practice. METHODS: This was a retrospective and multicenter study of consecutive psoriatic patients on risankizumab from April 2020 through November 2022...
March 5, 2024: Actas Dermo-sifiliográficas